The TEMPO Pilot Program: A New Era for Digital Health in Chronic Disease

The FDA has launched TEMPO (Technology Evaluation of Medical Products for Optimizing care), a groundbreaking pilot program designed to accelerate patient access to digital health technologies for chronic diseases. Announced on December 5, 2025, TEMPO represents a significant shift in how the agency approaches the regulation of software-based medical products. Here's what innovators, providers, and researchers need to know.

What is TEMPO?

TEMPO is a voluntary pilot program that provides an alternative regulatory pathway for certain digital health technologies focused on chronic disease management. The program is designed to balance the need for patient safety with the goal of getting beneficial technologies to patients faster.

The core innovation of TEMPO is its use of enforcement discretion. For products accepted into the pilot, the FDA will exercise enforcement discretion regarding certain premarket requirements, allowing manufacturers to collect real-world performance data after initial market entry. This data then informs ongoing regulatory oversight.

Key Features

• Risk-Based Approach: TEMPO is targeted at lower-risk digital health products where the potential benefits of early access outweigh the risks of delayed oversight.
• Real-World Performance Data: Manufacturers commit to collecting and submitting real-world data on product performance, safety, and patient outcomes post-launch.
• Iterative Oversight: The FDA will use the real-world data to inform ongoing regulatory decisions, including the potential for full market authorization or withdrawal from the market if safety concerns emerge.
• Defined Scope: The pilot is initially limited to specific chronic disease areas and use cases.

Eligible Disease Areas and Use Cases

The TEMPO pilot is initially focused on three chronic disease categories where digital health technologies have shown significant promise:

Eligible Product Types

Within these disease areas, the following types of digital health technologies may be eligible:

• Disease Management Apps: Software that helps patients monitor and manage their chronic conditions.
• Digital Therapeutics: Software intended to treat or improve clinical outcomes for specific conditions.
• Remote Patient Monitoring: Systems that enable healthcare providers to monitor patients outside of traditional clinical settings.
• Clinical Decision Support: Software that provides recommendations to clinicians based on patient data (subject to certain limitations).

The Regulatory Pathway in Detail

Manufacturers interested in TEMPO must follow a structured process:

Step 1: Statement of Interest

Manufacturers submit a Statement of Interest (SOI) to the FDA, describing their product, intended use, target patient population, and proposed real-world data collection plan. The SOI should also include any available safety and effectiveness data.

Step 2: FDA Review and Acceptance

The FDA reviews the SOI and determines whether the product meets the criteria for the pilot. If accepted, the FDA will work with the manufacturer to finalize the real-world data collection commitments and any specific conditions for market entry.

Step 3: Market Entry Under Enforcement Discretion

Once accepted, the manufacturer may begin marketing the product. The product should be clearly labeled to indicate its status in the TEMPO pilot and that it is not FDA approved or cleared.

Step 4: Real-World Data Collection and Reporting

The manufacturer collects real-world performance data according to the agreed-upon plan and submits periodic reports to the FDA. The frequency and content of these reports are determined during the acceptance process.

Step 5: Ongoing FDA Oversight

The FDA monitors the incoming data and may take action if safety concerns emerge. Possible outcomes include:

• Transition to Full Authorization: If the real-world data supports safety and effectiveness, the product may be granted full market authorization (510(k) clearance, De Novo, or PMA, as appropriate).
• Continued Pilot Status: If more data is needed, the product may remain in the pilot with additional data collection requirements.
• Withdrawal: If safety or effectiveness concerns arise, the FDA may end the enforcement discretion and require the product to be removed from the market or undergo traditional premarket review.

Opportunities for Innovators

TEMPO creates significant opportunities for digital health innovators, particularly those who have struggled with the traditional regulatory pathway.

Faster Time to Market

By deferring certain premarket requirements, TEMPO can significantly shorten the time from product development to market entry. For startups with limited resources, this can be the difference between success and failure.

Real-World Evidence Generation

The requirement for real-world data collection, while a burden, is also an opportunity. Manufacturers will generate robust real-world evidence that can support reimbursement claims, clinical adoption, and future regulatory submissions.

FDA Engagement

Participation in TEMPO provides a direct channel to the FDA. The iterative oversight model means manufacturers will have ongoing dialogue with the agency, building relationships and regulatory expertise.

"Home as Health Care Hub" Alignment

TEMPO is explicitly linked to the FDA's broader initiative on "Home as a Health Care Hub," which envisions a future where more healthcare is delivered in the home using digital technologies. Products that align with this vision are well-positioned for the pilot.

Challenges and Considerations

While TEMPO offers significant opportunities, manufacturers should also be aware of the challenges.

Not "Approval"

Products in the TEMPO pilot are not FDA approved or cleared. This may affect reimbursement, as payers often require FDA status for coverage. Manufacturers should engage payers early to discuss how pilot status will be handled.

Real-World Data Burden

The commitment to collect and report real-world data is not trivial. Manufacturers must have the infrastructure to capture, analyze, and submit this data on an ongoing basis. This requires investment in data systems and regulatory affairs resources.

Uncertainty

Unlike traditional approval, TEMPO does not guarantee permanent market access. Products remain subject to FDA action based on the incoming data. Manufacturers must be prepared for the possibility that their product could be required to undergo additional review or be withdrawn.

Labeling Requirements

Products in the pilot must be clearly labeled to indicate their status. This transparency is important for patients and providers but may also affect market perception.

How to Prepare

For manufacturers considering participation in TEMPO, here are the key steps to prepare:

1. Assess Eligibility

Review the FDA's guidance documents to determine whether your product falls within the eligible disease areas and use cases. If you're uncertain, request a Pre-Submission meeting with the FDA.

2. Design Your Real-World Data Strategy

The strength of your SOI will depend heavily on your proposed real-world data collection plan. Identify the key performance metrics, safety signals, and clinical outcomes you will track. Ensure you have the technical infrastructure to capture this data at scale.

3. Gather Existing Evidence

While TEMPO defers some premarket requirements, you should still have foundational evidence of safety and effectiveness. Compile any available data from internal testing, clinical studies, or prior deployments.

4. Engage Stakeholders

Discuss your TEMPO strategy with payers, health systems, and clinical partners. Understanding how they will view pilot status can inform your market access strategy.

5. Submit Your Statement of Interest

Follow the FDA's instructions for submitting your SOI. Be thorough, transparent, and responsive to FDA feedback.

Conclusion

The TEMPO pilot program represents a bold experiment in regulatory innovation. By balancing premarket rigor with real-world evidence generation, the FDA is attempting to create a pathway that is both faster and, ultimately, more informed by how products actually perform in the hands of patients.

For digital health innovators focused on chronic disease management, TEMPO is an opportunity not to be missed. It offers a chance to bring beneficial technologies to patients sooner while building the real-world evidence base that will be increasingly important for reimbursement and clinical adoption.

The program is new, and questions remain about how it will work in practice. But for those willing to embrace the uncertainty and commit to rigorous real-world data collection, TEMPO could be a game-changer.

Want to stay ahead of digital health regulatory developments? Subscribe to the CTDSU newsletter for weekly insights and analysis.